Luis F. Angel, MD
President and Chief Medical Officer
Dr. Angel is BiO2 Medical’s President and Chief Medical Officer and will be responsible for implementing the scientific agenda for the company. Dr. Angel is an Associate Professor of Pulmonary and Critical Care Medicine, Director of Lung Transplantation, and Director of Interventional Pulmonary Medicine at the University of Texas Health Science Center at San Antonio.
During Dr. Angel’s fellowship in interventional pulmonology at Harvard Medical School, he developed a stent delivery device that was eventually commercialized by Merit Medical and is currently sold in the United States and Europe as the Aero Direct Visualization Delivery System. Dr. Angel then developed the Angel® Catheter with the goal of preventing PEs in critically ill patients.
Christopher E. Banas
Chief Executive Officer, Chairman of the Board
BiO2 Medical’s Chairman and Chief Executive Officer, Christopher E. Banas, is a medical device industry veteran with extensive, directly applicable leadership experience in cardiovascular company startup, financing, management, R&D, scale-up, regulatory approval, and commercialization.
Mr. Banas has co-founded four medical device companies, Advanced Bio Prosthetic Surfaces, Ltd. (ABPS), CardioSpectra, Inc., Aeon BioScience Inc., and BiO2 Medical, Inc., all in the cardiovascular space. ABPS and CardioSpectra successfully developed their respective products, demonstrated feasibility, and were sold to major, US based medical device companies. Aeon BioScience is currently developing an elastin-based biomaterial to be used either as a coating for medical devices to improve their biological properties, or as a stand-alone material, such as a small diameter vascular graft to be used as a bypass graft.
CardioSpectra, developed an Optical Coherence Tomography (OCT) imaging catheter, console, and interface device for the high resolution imaging of coronary and peripheral arteries. Banas and his team raised the capital, developed the products, and conducted all relevant in-vitro, and in-vivo testing to gain a CE Mark. CardioSpectra was then sold to Volcano Corporation, a publically held medical device company, where Banas assumed the role of President and General Manager for their new OCT division.
Prior to CardioSpectra, Mr. Banas co-founded Advanced Bio Prosthetic Surfaces, Ltd. (ABPS) with Dr. Julio Palmaz, the inventor of the balloon expandable Palmaz® stent. Under Mr. Banas’ leadership as President and CEO, he raised the capital and developed an entirely new method for making Nitinol implantable cardiovascular devices utilizing physical vapor deposition. Banas and his team developed the technology, demonstrated feasibility through numerous bench and animal testing, conducted a First in Man (FIM) human clinical trial, and then sold the exclusive license to practice the technology to Cordis, a Johnson and Johnson company.
Mr. Banas holds 61 issued US patents and currently has 65 published US applications in the fields of cardiovascular medicine, specifically, vascular surgery, interventional cardiology, nanotechnology and physical vapor deposition of NITINOL.
Mr. Frederickson has over 20 years of financial, marketing and medical device experience. His background includes experience in new product development, strategy consulting, investment management, investment banking, and medical device management.
Mr. Frederickson has nearly 10 years of medical device experience in strategy, business development, marketing, and financial management roles. Prior to joining BiO2 Medical, he worked with W.L. Gore & Associates Medical Products Division for several years in new business development, strategic planning, and general management roles. Before that Mr. Frederickson was a financial leader at Angiotech Pharmaceuticals, where he held a variety of roles and helped navigate a restructuring and bankruptcy, and commercialized several products.
Prior to his experience in Medical Devices, Mr. Frederickson worked in investment banking, specializing in Mergers & Acquisitions. He completed 20 investment banking transactions while working with Dresner Partners and Houlihan Lokey. His other experience includes several years of management consulting and investment analysis with Deloitte and the Vanguard Group.
Mr. Frederickson obtained a MBA from the University of Chicago Booth School of Business and a BBA in Finance from the University of Georgia Terry College of Business. He is also a Chartered Financial Analyst (CFA).
Julie Ross joined BiO2 Medical, Inc. as the Director of Quality Assurance and Regulatory Affairs. She has 30 years of medical device experience with a broad regulatory compliance, quality systems, and quality assurance background.
Prior to joining the company, Ms. Ross held positions as Plant Quality Manager, Regulatory Compliance Director, and Senior Regulatory Associate at Covidien, and various RQA positions with Baxter Edwards CVS and Sorin Biomedical. She holds a B.S. in Microbiology from California State University in Long Beach, California, and is an ISO 13485 Lead Auditor.
Jeff Steinmetz is the Vice President of Research and Development for BiO2 Medical, Inc. He has over 10 years of medical device experience.
After receiving his B.S. in Mechanical Engineering from the University of Portland, he began his medical device career with Chris Banas at Advanced Bio Prosthetic Surfaces, Ltd. (ABPS), as a R&D Project Engineer. He was responsible for the design, prototyping and characterization of Class III Nitinol medical devices.
His design experience includes coronary stents, surgical grafts, AAA stent grafts, heart valves, venous valves, septal occluders, embolic protection devices, vena cava filters, and catheter based delivery systems. Since he joined BiO2 Medical in 2007, Jeff has continued to apply his creativity and management to the development of the Angel® Catheter and future product roadmap.
Joseph Piercy serves as BiO2 Medical’s Secretary and General Manager, EMEA. His duties include overseeing the day-to-day financial and corporate affairs of the company.
Mr. Piercy has been continuously employed with the same core group of individuals since 1999, through two previously successful startup companies, Advanced Bio Prosthetic Services Ltd. (ABPS) and CardioSpectra, Inc. During these years, Mr. Piercy has served in various engineering and management capacities.